1. Home
  2. NMZ vs ZYME Comparison

NMZ vs ZYME Comparison

Compare NMZ & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

NMZ

Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

N/A

Current Price

$8.75

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$26.24

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMZ
ZYME
Founded
2003
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2003
2022

Fundamental Metrics

Financial Performance
Metric
NMZ
ZYME
Price
$8.75
$26.24
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $43.23
AVG Volume (30 Days)
★ 1.9M
1.2M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 5.08%
N/A
EPS Growth
N/A
★ 33.33
EPS
N/A
★ 1.08
Revenue
N/A
★ $105,965,000.00
Revenue This Year
N/A
$216.20
Revenue Next Year
N/A
$7.81
P/E Ratio
★ N/A
$24.65
Revenue Growth
N/A
★ 38.87
52 Week Low
$8.62
$21.52
52 Week High
$10.74
$31.97

Technical Indicators

Market Signals
Indicator
NMZ
ZYME
Relative Strength Index (RSI) 41.54 41.75
Support Level $8.67 $25.21
Resistance Level $9.19 $27.40
Average True Range (ATR) 0.13 1.41
MACD 0.01 -0.33
Stochastic Oscillator 12.35 5.69

Price Performance

Historical Comparison
NMZ
ZYME

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: